Tiny stem-cell firms close in on major goals for heart disease
NEW YORK (Reuters) – The early hope that stem-cell therapy would make the paralyzed walk, the blind see and cure diabetes has given way to a long list of failures, highlighted by early stem-cell champion Geron Corp. abandoning the field in 2011.
But two small companies, Athersys Inc. and Mesoblast Ltd., are beginning final-stage trials in hundreds of patients that they – along with loyal investors – say could change the course of devastating stroke and heart failure.
Both have overcome major hurdles to manufacturing stem-cell treatments on a large scale that are off-theshelf products derived from healthy donor bone marrow and do not face immune-system rejection issues.
Cleveland-based Athersys, with a market value of about $200 million, demonstrated evidence in a midstage trial that its therapy may be able to expand the emergency treatment window for major strokes to up to 36 hours, compared with about four hours with current drugs, potentially allowing many more patients to avoid crippling disabilities.
Australia’s Mesoblast, with a market value of about $500m., is attempting to alter advanced heart failure, a leading cause of hospitalizations and deaths and an enormous cost burden.
They are among the farthest along in the stem-cell industry at a time when Wall Street investors have focused on potentially big payoffs from immune-system-based cancer therapies and rare-disease treatments.
Perception of the field has also been hurt by unscrupulous actors selling unapproved, possibly unsterile cell therapies for cancer, lung disease, ALS and other ailments, prompting a US crackdown this past summer.
“The market tends to test these companies sometimes to the brink,” said Tom Dobell, who manages a fund for UK-based M&G Investment Management that specializes in supporting promising companies during difficult periods. “We’re comfortable that the progress that’s going on is going to be worth it.”
M&G is a longtime holder of Mesoblast, with about a 15% stake, and Athersys, with about 4%.
Athersys’s experimental Multistem treatment was one of the first companies to be designated by the US Food and Drug Administration as a promising cell-based therapy with potential to address unmet needs for serious or life-threatening conditions, potentially easing the approval process.
FDA Commissioner Scott Gottlieb said in a recent interview the agency is seeking an approval pathway for legitimate stem-cell therapies “that’s not overly burdensome.”
“The regenerative-medicine space has been a tough road clinically, and Athersys is one of the bright, shining stars,” said Steven Martin, a managing member of Chicago-based Aspire Capital and a longtime holder of Athersys shares.
REDUCING THE RISKS
Athersys believes Multistem – 1.2 billion cells delivered via simple intravenous drip – dampens the immune system’s hyper-inflammatory reaction to signals that the brain is under attack during stroke and promotes healing.
The body’s reaction to stroke may also severely deplete the immune system, leading to later complications beyond paralysis or speech impairment. In the Phase II trial, Multistem patients had significantly fewer incidents of pneumonia, acute pulmonary distress and other serious complications.
That trial, attempting to extend the treatment window to 48 hours, failed. But researchers were encouraged by patients treated up to 36 hours post stroke.
“It’s reason to be cautiously optimistic,” said Dr. Ken Uchino, a leading Multistem investigator from the Cleveland Clinic.
The company plans to begin a 300-patient Phase III study of Multistem in early 2018, aiming for US and European approval after regulators agreed to protocols for one pivotal trial.
“This reinforces and cements an efficient path forward for us,” Athersys chief executive Gil Van Bokkelen said.
A separate 220-patient Multistem trial in Japan for that market began enrolling patients through partner Healios KK.
“Of the many entities in this field, they have been careful and deliberate in their movement forward” and do not engage in “overwrought claims,” said Dr. S. Thomas Carmichael, a co-director of the UCLA Broad Stem Cell Center, who was not involved in Multistem trials.
Mesoblast’s MPC-150-IM therapy aims to mitigate advanced heart failure, a progressive condition in which the heart cannot pump enough blood to efficiently serve the body.
The company believes the therapy reduces inflammation, increases blood flow and spurs blood-vessel formation that helps repair the heart muscle. A single dose consists of 150 million highly purified stem cells delivered directly to the heart’s left ventricle by injection or catheter.
An ongoing Phase III trial of 600 advanced heart-failure patients is currently enrolling. Reducing the severity of a patient’s heart failure “would give them back potentially many years of good-quality life,” Mesoblast CEO Silviu Itescu said.
Independent monitors who oversee and can halt blinded clinical trials for futility gave a green light to continue the Mesoblast study in April after a review of the first 270 treated patients, suggesting the therapy might be effective.